World News: 10:36 GMT Friday 2nd August 2019. [Boehringer Ingelheim via Businesswire via SPi World News]
Boehringer Ingelheim today announcedinterim analysis from the GioTag study showing that initiating with afatinib followed by osimertinib an overall survival OS of four years 457 months in patients wi th Del1...
Business Wire: 10:36 GMT Friday 2nd August 2019
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.